HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price target from $4 to $5.
- Company Dashboard
- Filings
- Patents
-
Article
HC Wainwright & Co. Maintains Buy on Context Therapeutics, Raises Price Target to $5
Company Profile